Lv4
500 积分 2024-04-11 加入
OP0137 EFFICACY AND SAFETY OF TELITACICEPT, A NOVEL BLYS/APRIL DUAL INHIBITOR, IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED 52-WEEK STUDY
6天前
已完结
Wang L, Li J, Xu D, Fang J, Van Vollenhoven R, Zhang F. OP0137 Efficacy and safety of telitacicept, a novel blys/april dual inhibitor, in patients with systemic lupus erythematosus: a phase 3, randomized, placebo-controlled 52-week study. Ann Rheum Dis (2023) 82:90–1. doi: 10.1136/annrheumdis-2023-eular.1727
6天前
已关闭
Deucravacitinib shows superior efficacy and safety in cutaneous lupus erythematosus compared to various biologics and small molecules – A systematic review and meta-analysis
21天前
已完结
Deucravacitinib shows superior efficacy and safety in cutaneous lupus erythematosus compared to various biologics and small molecules - A systematic review and meta-analysis
24天前
已完结
Mortality and adverse events of special interest with intravenous belimumab for adults with active, autoantibody-positive systemic lupus erythematosus (BASE): a multicentre, double-blind, randomised, placebo-controlled, phase 4 trial
1个月前
已完结
Baricitinib for systemic lupus erythematosus: a double- blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II)
1个月前
已完结
皖公网安备34019202002308
